Clicky

Denali Therapeutics Inc.(DNLI)

Description: Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.


Keywords: Biopharmaceutical Organ Systems Alzheimer's Disease Neuroscience Parkinson's Disease Neurological Disorders Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Degenerative Disease Neurodegeneration Senescence

Home Page: www.denalitherapeutics.com

DNLI Technical Analysis

161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone: 650 866 8548


Officers

Name Title
Dr. Ryan J. Watts Ph.D. Co-Founder, Pres, CEO & Director
Dr. Alexander O. Schuth M.D. Co-Founder, CFO, COO & Sec.
Dr. Marc Tessier-Lavigne Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Dr. Carole Ho M.D. Chief Medical Officer & Head of Devel.
Mr. Steve Edward Krognes Treasurer & Director
Mr. Tyler M. Nielsen Sr. VP of Corp. Fin.
Dr. Dana Andersen Chief Technical and Manufacturing Officer
Mr. Joe Lewcock Chief Scientific Officer
Dr. Laura Hansen VP of Investor Relations
Mr. Chris Walsh Gen. Counsel

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.7475
Price-to-Sales TTM: 35.6178
IPO Date: 2017-12-08
Fiscal Year End: December
Full Time Employees: 413
Back to stocks